A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.
Visium, which provides gene expression information along with spatial information from the same tissue sample, will be shipped later next month.
The company reported $10.7 million in total revenues for the quarter and said test report volume for its DecisionDx-Melanoma test grew 27 percent.
In PNAS this week: intronic STAT3 splice site linked to autosomal dominant primary immunodeficiency condition, human B lymphocyte changes following Epstein-Barr virus exposure, and more.
Using samples from heart failure patients and healthy controls, researchers uncovered a gene that, when absent in mice, reduced their risk of heart failure.
MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.
Most head and neck cancer patients saw a decline in oral HPV DNA after treatment, but those who did not were more likely to experience disease recurrence.
The signature is enriched for genes involved in immune-related processes, such as T cell co-stimulation and antigen presentation, and suggests personalized treatments.
Researchers traced genomic, epigenomic, and expression features in lung carcinoma in situ cases that regressed or progressed to invasive lung squamous cell carcinomas.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.